echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > my country's first child-specific organ transplant immunosuppressant approved for marketing

    my country's first child-specific organ transplant immunosuppressant approved for marketing

    • Last Update: 2021-06-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    my country's first child-specific organ transplant immunosuppressant approved for marketing
    my country's first child-specific organ transplant immunosuppressant was approved for marketing my country's first child-specific organ transplant immunosuppressant was approved for marketing

    Children's organ transplantation is an effective means to treat children with congenital or end-stage liver and kidney diseases.


    Statistics show that in 2018, the annual number of children's liver transplants in my country exceeded 1,000 for the first time.


    In the May 29 Shanghai's "love • Precision delivers hope" Ireland reusable Chinese listed on the meeting, credits will be children's organ transplant study group leader of Chinese Medical Association of Organ Transplantation, Shanghai Jiaotong University School of Medicine, Renji Hospital, hospital long and primary liver surgery professor Renxia Jiang said: "the number of children of organ transplants increased year by year, is listed on the Irish reusable precise treatment concept once again advance, will bring the refinement of the treatment and management of children's organ transplants in children, Achieve long-term survival.


    Dean

    Chinese Medical Association credits will designate an organ transplant director committee member , First Affiliated Hospital of Xi'an Jiaotong University, kidney disease hospital president Professor XUE said: "The organ allograft rejection is one of the important causes of poor transplantation, transplantation and early The refined and individualized optimized immunosuppressive program for the maintenance phase after transplantation is essential to improve the long-term prognosis of patients and increase the survival rate.


    Committee president

    The drug dose or blood concentration of immunosuppressants is a key factor that affects the efficacy of the drug, and its small changes can cause related serious adverse reactions or lead to treatment failure.


    Professor Wang Changxi, Director of the Organ Transplantation Department of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, said: “Children’s kidney transplantation can improve the growth, development and cognitive abilities of children, and save the lives of children with uremia to the greatest extent.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.